This study assessed the efficacy of PCSK9 inhibitors in reducing MACE, nonfatal myocardial infarction, stroke, cardiovascular death, and all-cause mortality in statin-intolerant patients. The gene discussed is PCSK9; the disease is myocardial infarction.